Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Phase III Study of Oralgen Grass Pollen in Grass Pollen-related Allergic Rhinoconjunctivitis
2008-004825-40Phase 3Terminated
- Sponsor
- Artu Biologicals
- Start
- Sep 2008
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing Oralgen Grass Pollen with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint (season 3 combined RTSS/RMS score). Started Sep 2008; status: terminated.
02
Drugs
Oralgen Grass Pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2008-004825-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004825-40.